



PRESS RELEASE
27 June 2025 13:00:00 CEST

Stockholm3 included in NCCN guidelines for Prostate Cancer Early Detection

As of June 2025, Stockholm3 has been included as a diagnostic tool for biopsy decision-making in the updated NCCN Clinical Practice Guidelines for Prostate Cancer Early Detection.

The National Comprehensive Cancer Network® (NCCN®) is a leading US authority in clinical practice standards for cancer care. Stockholm3 has been added to the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer Early Detection, Version 2.2025 [1]. The NCCN guidelines state the probability of high-grade cancer (Grade Group ≥ 2) may be further defined prior to initial biopsy utilizing tools such as Stockholm3. Stockholm3 is categorized as a 2A-level recommendation indicating uniform consensus among NCCN panel experts that Stockholm3 is an appropriate option based on current evidence.

“The inclusion of Stockholm3 in the NCCN guidelines confirms its clinical relevance and further establishes our test as a powerful tool in the early detection of high-grade prostate cancer,” said Martin Steinberg, Executive Chairman of A3P Biomedical.

“This is an important milestone in our mission to advance precision diagnostics in prostate cancer,” Martin Steinberg concluded.

The NCCN’s recognition adds to the growing international momentum of Stockholm3 and strengthens its positioning for broader adoption across clinical settings. With the burden of prostate cancer continuing to rise globally, there is increasing demand for screening tools that enable more accurate, earlier, and less invasive diagnosis.

[1] Moses, KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall’Era M, Davis JW, Drake BF, Eggener S, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Lotan T, Maroni P, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Shoag J, Smaldone MC, Sonn G, Tyson II MD, Vapiwala N, Wake R, Washington III S, Yu A, Yuh B, Freedman-Cass D, Howley R, Kovach E. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Early Detection v2.2025. Accessed 06/24/25. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org)

For additional information, please contact:

Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com

A3P Biomedical AB (publ)



About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P's main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com

About Stockholm3

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit www.stockholm3.com/

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

Attachments

[Stockholm3 included in NCCN guidelines for Prostate Cancer Early Detection](#)